Role of Diffusion -Weighted MRI in Evaluation of Urinary Bladder Masses

Status Not yet recruiting

Clinical Trial Summary

Urinary bladder cancer is a common malignant tumor of the urinary tract in both men and women. Proper management of the urinary bladder cancer depends on the stage of the lesions. Differentiating the histopathological types, tumor grade and the depth of tumor invasion are very important for determining the therapeutic approach and are highly correlated with the recurrence, progression and patient's survival. Radical cystectomy (RC) and lymphadenectomy after neoadjuvant chemotherapy is the standard treatment for muscle invasive tumors, whereas the treatment of choice for non-muscle invasive tumors is transurethral resection (TUR) ±chemo/immunotherapy. Cystoscopy with biopsy is still the best tool for bladder cancer staging due to its high sensitivity in detecting lesions and the possibilities of tumor resections, but the main drawbacks are invasiveness, limitation in detection of flat lesions, and lack of the assessment of extra-vesical tumor invasion. Modern diagnostic modalities circumvent these limitations like blue-light cystoscopic examination and infrared cystoscopy. For the radiological evaluation of the urinary bladder, magnetic resonance imaging (MRI) is a valuable imaging modality due to high tissue contrast and multiplanar imaging capabilities. Diffusion-weighted images provides useful information for evaluation of local T stage of the urinary bladder cancer, specially in differentiating T1 stage or lower tumors from T2 stage and higher tumor stages. Apparent diffusion coefficient (ADC) delineating the degree of water molecular diffusion and the degree of restriction to water diffusion in biological tissues is inversely correlated to the integrity of the cell membranes and the tissue cellularity. The apparent diffusion coefficient (ADC) value has been revealed as quantitative measure of the degree of malignancy of the lesions. Decreased ADC values were reported with malignant lesions which have a larger cell diameter and more cellularity than normal tissue.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05097105
Study type	Observational
Source	Sohag University
Contact	Walaa R Abdellah, assistant lecture
Phone	01099870794
Email	walaa.mahmoud@med.sohag.edu.eg
Status	Not yet recruiting
Phase
Start date	November 2021
Completion date	November 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05429710` - SOX2 & PDL1 Expression on Urinary Bladder Carcinoma
Completed	`NCT02977143` - Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery	N/A
Completed	`NCT02966535` - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial	N/A
Recruiting	`NCT04144270` - The Importance of Muscle Function in Patients With Disseminated Bladder Cancer
Completed	`NCT05946369` - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Recruiting	`NCT05786716` - DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations	Phase 2/Phase 3
Recruiting	`NCT06238479` - A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT02311101` - Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer	Phase 1
Recruiting	`NCT04811846` - CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood	N/A
Recruiting	`NCT04576286` - Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary Bladder	Phase 3
Completed	`NCT02857634` - Confocal Microscopy Dual Band in the Management of Bladder Cancer
Recruiting	`NCT04561362` - Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies	Phase 1/Phase 2
Recruiting	`NCT04442724` - Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy	N/A
Recruiting	`NCT04029948` - Laser vs. Electorsurgical Enbloc Resection of Bladder Tumours	N/A
Terminated	`NCT03389438` - Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma	Phase 2
Terminated	`NCT02952989` - A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06237920` - Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab	Phase 2
Completed	`NCT03785925` - A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer	Phase 2
Completed	`NCT03636256` - Evaluation of NanoDoce® in Participants With Urothelial Carcinoma	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.